Task-Shifting Strategy for High Blood Pressure in HIV Care

(TASSH NIMR Trial)

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen by Olugbenga Ogedegbe, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: NYU Langone Health

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests a new approach to help HIV patients with high blood pressure in Lagos, Nigeria. Experts will train and support nurses to better manage blood pressure in these patients, aiming to reduce heart disease risks.

Research Team

Olugbenga Ogedegbe, MD

Principal Investigator

NYU Langone Health

Eligibility Criteria

This trial is for adults over 18 with HIV/AIDS who also have high blood pressure (140-179/90-100 mm Hg) and are receiving care at one of the 30 designated HIV clinics. It's not open to those with extremely high blood pressure, chronic kidney disease, heart disease, diabetes, stroke history, or pregnant individuals.

Inclusion Criteria

Ability to provide consent

My blood pressure is high, between 140-179 over 90-100 mm Hg.

Attends one of the 30 HIV clinics.

Exclusion Criteria

Inability to provide informed consent

I have a history of chronic kidney disease, heart disease, diabetes, stroke, or am pregnant.

I do not want to participate in the study.

Treatment Details

Interventions

• Task-shifting strategy for HTN control (TASSH) protocol (Behavioral Intervention)

Trial Overview The study is testing a tailored-practice facilitation strategy called TASSH aimed at integrating hypertension management into existing HIV care services within primary health centers in Lagos, Nigeria.

Participant Groups

Group I: With Practice Facilitation (PF) Experimental Treatment 1 Intervention

Participants will be identified from HIV clinics during routine visits and will receive the task-shifting strategy for HTN control (TASSH) protocol.

Group II: Self-directed without Practice Facilitation (PF) Active Control 1 Intervention

Participants will be identified from HIV clinics during routine visits and provided standard of care.

Who Is Running the Clinical Trial?

NYU Langone Health

Lead Sponsor

Trials

1,431

Recruited

838,000+

Dr. Alec C. Kimmelman

NYU Langone Health

Chief Executive Officer

MD and PhD from Mount Sinai School of Medicine

Dr. Nicole M. Adler

NYU Langone Health

Chief Medical Officer since 2023

MD

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials

3,987

Recruited

47,860,000+

Dr. Gary H. Gibbons

National Heart, Lung, and Blood Institute (NHLBI)

Chief Executive Officer since 2012

MD from Harvard Medical School

Dr. James P. Kiley

National Heart, Lung, and Blood Institute (NHLBI)

Chief Medical Officer since 2011

MD from University of California, San Francisco